ADAG – Adagene Inc.
[iframe https://s.tradingview.com/embed-widget/symbol-info/?locale=in&symbol=ADAG#%7B%22symbol%22%3A%22A%22%2C%22width%22%3A%22100%25%22%2C%22colorTheme%22%3A%22light%22%2C%22isTransparent%22%3Atrue%2C%22height%22%3A203%2C%22utm_source%22%3A%22themarketstracker.com%22%2C%22utm_medium%22%3A%22widget_new%22%2C%22utm_campaign%22%3A%22symbol-info%22%7D 900 250 ]
ADAG — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
1.59
Margin Of Safety %
Put/Call OI Ratio
EPS Next Q Diff
EPS Last/This Y
-0.21
EPS This/Next Y
-0.01
Price
3.63
Target Price
9.4
Analyst Recom
1.33
Performance Q
28.42
Upside
-231.4%
Beta
0.57
Ticker: ADAG
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-04-15 | ADAG | 3.82 | N/A | N/A | 0 |
| 2026-04-16 | ADAG | 3.83 | N/A | N/A | 0 |
| 2026-04-17 | ADAG | 3.93 | N/A | N/A | 0 |
| 2026-04-20 | ADAG | 3.85 | N/A | N/A | 0 |
| 2026-04-21 | ADAG | 3.77 | N/A | N/A | 0 |
| 2026-04-22 | ADAG | 3.77 | N/A | N/A | 0 |
| 2026-04-23 | ADAG | 3.74 | N/A | N/A | 0 |
| 2026-04-24 | ADAG | 3.68 | N/A | N/A | 0 |
| 2026-04-27 | ADAG | 3.57 | N/A | N/A | 0 |
| 2026-04-28 | ADAG | 3.54 | N/A | N/A | 0 |
| 2026-04-29 | ADAG | 3.55 | N/A | N/A | 0 |
| 2026-04-30 | ADAG | 3.65 | N/A | N/A | 0 |
| 2026-05-01 | ADAG | 3.8 | N/A | N/A | 0 |
| 2026-05-04 | ADAG | 3.68 | N/A | N/A | 0 |
| 2026-05-05 | ADAG | 3.61 | N/A | N/A | 0 |
| 2026-05-06 | ADAG | 3.65 | N/A | N/A | 0 |
| 2026-05-07 | ADAG | 3.58 | N/A | N/A | 0 |
| 2026-05-08 | ADAG | 3.67 | N/A | N/A | 0 |
| 2026-05-11 | ADAG | 3.75 | N/A | N/A | 0 |
| 2026-05-12 | ADAG | 3.7 | N/A | N/A | 0 |
| 2026-05-13 | ADAG | 3.67 | N/A | N/A | 0 |
| 2026-05-14 | ADAG | 3.65 | N/A | N/A | 0 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-04-15 | ADAG | 3.85 | - | - | -0.51 |
| 2026-04-16 | ADAG | 3.84 | - | - | -0.51 |
| 2026-04-17 | ADAG | 3.95 | - | - | -0.51 |
| 2026-04-20 | ADAG | 3.88 | - | - | -0.51 |
| 2026-04-21 | ADAG | 3.77 | - | - | -0.51 |
| 2026-04-22 | ADAG | 3.77 | - | - | -0.51 |
| 2026-04-23 | ADAG | 3.74 | - | - | -0.51 |
| 2026-04-24 | ADAG | 3.68 | - | - | -0.51 |
| 2026-04-27 | ADAG | 3.57 | - | - | -0.51 |
| 2026-04-28 | ADAG | 3.50 | - | - | -0.51 |
| 2026-04-29 | ADAG | 3.55 | - | - | -0.51 |
| 2026-04-30 | ADAG | 3.62 | - | - | -0.51 |
| 2026-05-01 | ADAG | 3.81 | - | - | -0.51 |
| 2026-05-04 | ADAG | 3.68 | - | - | -0.51 |
| 2026-05-05 | ADAG | 3.63 | - | - | -0.51 |
| 2026-05-06 | ADAG | 3.61 | - | - | -0.51 |
| 2026-05-07 | ADAG | 3.60 | - | - | -0.51 |
| 2026-05-08 | ADAG | 3.65 | - | - | -0.51 |
| 2026-05-11 | ADAG | 3.76 | - | - | -0.51 |
| 2026-05-12 | ADAG | 3.70 | - | - | -0.51 |
| 2026-05-13 | ADAG | 3.67 | - | - | -0.51 |
| 2026-05-14 | ADAG | 3.63 | - | - | -0.51 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-04-15 | ADAG | 0.00 | -6.88 | 0.18 |
| 2026-04-17 | ADAG | 0.00 | -6.88 | 0.18 |
| 2026-04-20 | ADAG | 0.00 | -6.88 | 0.18 |
| 2026-04-21 | ADAG | 0.00 | -6.88 | 0.18 |
| 2026-04-22 | ADAG | 0.00 | -6.88 | 0.18 |
| 2026-04-23 | ADAG | 0.00 | -6.88 | 0.18 |
| 2026-04-24 | ADAG | 0.00 | -6.88 | 0.18 |
| 2026-04-27 | ADAG | 0.00 | -6.90 | 1.04 |
| 2026-04-28 | ADAG | 0.00 | -6.90 | 1.04 |
| 2026-04-29 | ADAG | 0.00 | -6.90 | 1.04 |
| 2026-04-30 | ADAG | 0.00 | -6.90 | 1.04 |
| 2026-05-01 | ADAG | 0.00 | -6.90 | 1.04 |
| 2026-05-04 | ADAG | 0.00 | -6.90 | 1.04 |
| 2026-05-05 | ADAG | 0.00 | -6.90 | 1.04 |
| 2026-05-06 | ADAG | 0.00 | -6.90 | 1.04 |
| 2026-05-07 | ADAG | 0.00 | -6.90 | 1.04 |
| 2026-05-08 | ADAG | 0.00 | -6.90 | 1.04 |
| 2026-05-11 | ADAG | 0.00 | -6.90 | 1.04 |
| 2026-05-12 | ADAG | 0.00 | -6.90 | 1.67 |
| 2026-05-13 | ADAG | 0.00 | -6.90 | 1.67 |
| 2026-05-14 | ADAG | 0.00 | -6.90 | 1.59 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
[iframe https://widget.finnhub.io/widgets/historical-eps?symbol=ADAG 589 360 ]
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
-0.15
Avg. EPS Est. Next Quarter
-0.19
Insider Transactions
Institutional Transactions
-6.9
Beta
0.57
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
30
Growth Score
33
Sentiment Score
79
Actual DrawDown %
82.7
Max Drawdown 5-Year %
-95.6
Target Price
9.4
P/E
Forward P/E
PEG
P/S
22.55
P/B
4.91
P/Free Cash Flow
EPS
-0.37
Average EPS Est. Cur. Y
-0.51
EPS Next Y. (Est.)
-0.52
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-229.49
Relative Volume
0.01
Return on Equity vs Sector %
-76.7
Return on Equity vs Industry %
-61.2
EPS 1 7Days Diff
0.2
EPS 1 30Days Diff
0.21
EBIT Estimation
[iframe https://widget.finnhub.io/widgets/recommendation?symbol=ADAG 589 450 ]
[iframe https://widget.finnhub.io/widgets/eps-estimate?symbol=ADAG 589 450 ]
◆
ADAG
Healthcare
$3.66
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
48.2
Range 1M
49.9%
Sup Dist
1.1%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
-61.7%
EPS NY
-3.1%
52W%
68.2%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+156.8% upside
Upside
+156.8%
Quality
30
Adagene Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 128
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. Adagene Inc. was incorporated in 2011 and is headquartered in Suzhou, China.
ADAG
Latest News
—
Caricamento notizie per ADAG…
stock quote shares ADAG – Adagene Inc. Stock Price stock today
news today ADAG – Adagene Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ADAG – Adagene Inc. yahoo finance google finance
stock history ADAG – Adagene Inc. invest stock market
stock prices ADAG premarket after hours
ticker ADAG fair value insiders trading